WilmerHale Advising AVEO Oncology in Sale to LG Chem

• 10.21.2022

WilmerHale is advising AVEO Oncology on its pending sale to LG Chem in an all-cash transaction with an implied equity value of approximately $566 million. Headquartered in Massachusetts, AVEO Oncology is a biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. In 2021, AVEO Oncology received FDA approval for FOTIVDA® (tivozanib), the first therapy approved for adult patients with relapsed or refractory advanced renal cell carcinoma. 
 
Based in Seoul, South Korea, LG Chem is a leading global chemical company with a diversified business portfolio in the key areas of petrochemicals, advanced materials and life sciences.

Read more.